Articles with the topic: featured

Huntington’s disease therapeutics conference 2023 - Day 1

Huntington’s disease therapeutics conference 2023 - Day 1

Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2023

Joel Stanton, Dr Rachel Harding, Dr Leora Fox, and Dr Tamara MaiuriApril 26, 2023

PROOF-HD study of pridopidine ends with negative result

PROOF-HD study of pridopidine ends with negative result

The phase 3 trial missed its primary endpoint of slowing loss of function in Huntington’s disease

Professor Ed WildApril 25, 2023

Astrocytes: The new star in HD research?

Astrocytes: The new star in HD research?

A new article summarizes what the Huntington's disease field has found about a type of brain cell called an astrocyte. These star-shaped cells help keep brain cells healthy and could be leveraged for developing new HD therapeutics.

Dr Sarah HernandezApril 19, 2023

Hunting for balance: how the huntingtin protein compensates in HD

Hunting for balance: how the huntingtin protein compensates in HD

Researchers look at the cause and effect of various forms of the HTT protein. They find both expanded and unexpanded HTT contribute to brain cell communication and the brain has an amazing capacity to compensate for changes related to disease

Dr Sarah Hernandez and Dr Leora FoxApril 05, 2023

Roche Phase II GENERATION HD2 study underway

Roche Phase II GENERATION HD2 study underway

Roche released a community letter in early 2023, to share that their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. In this article, we summarise the latest news about this huntingtin-lowering drug.

Dr Rachel HardingFebruary 14, 2023

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Novartis have announced that they are ending development of the drug branaplam in Huntington’s disease. Here, we review this latest news and its impact on the HD community.

Dr Rachel HardingDecember 09, 2022

uniQure gets the green light to resume testing HD gene therapy

uniQure gets the green light to resume testing HD gene therapy

Following a 3-month pause in enrollment due to concerns about side effects, uniQure shared the good news that their trial of the HD gene therapy AMT-130 will continue as planned, with new safety measures in place.

Dr Leora FoxNovember 03, 2022

Update on the PTC Therapeutics PIVOT-HD Trial

Update on the PTC Therapeutics PIVOT-HD Trial

Last week, PTC Therapeutics released a statement sharing that recruitment of participants into the US arm of the PIVOT-HD trial has been paused. In this article, we will lay out exactly what is known and what this announcement means.

Dr Rachel Harding and Dr Leora FoxNovember 03, 2022

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. Let’s talk about the history and the caveats surrounding these hopeful pieces of news.

Dr Jeff Carroll and Dr Leora FoxSeptember 30, 2022

Donate

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community.

With your support, we can ensure the continuity of our services. Nothing is expected, but everything is appreciated and sustains what we do at HDBuzz. Please consider giving what you're able. More information...